linjc16/ctgov huggingface dataset:
Bioimpedance Spectroscopy for the Differential Diagnosis of Hyponatremia

Study Overview
=================
Brief Summary
-----------------
We aimed to investigate the role of bioimpedance spectroscopy for the diagnosis of hyponatremia

Detailed Description
-----------------
Up to now, Hyponatremia differentially diagnosed by physical examination, plasma and urine osmolalities, Echocardiography and biochemical measurements. The purpose of this study is to determine whether bioimpedance spectroscopy can be used for the detection of hypovolemia and hypervolemia for the differential diagnosis of hyponatremia.

Official Title
-----------------
Bioimpedance Spectroscopy for the Differential Diagnosis of Hyponatremia

Conditions
-----------------
Hyponatremia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing to participate in the study with written informed consent Older than 18-years Exclusion Criteria: The presence of pacemaker or defibrillator Artificial joints, pin or amputation Pregnancy or lactating.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hypovolemic hyponatremia<br>Negative values of Overhydration measured by Bioimpedance spectroscopy | |
| Hypervolemic hyponatremia<br>Positive values of Overhydration measured by Bioimpedance spectroscopy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of volume status measured by bioimpedance spectroscopy | BIOIMPEDANCE SPECTROSCOPY: Overhydration (OH) measurement by Body Composition Monitor (Fresenius Medical Care) Negative values of OH indicating Hypovolemia and positive values for hypervolemia in hyponatremic patients. | Six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Laboratory data and echocardiography | LABORATORY MEASUREMENTS Hemoglobin, Hematocrit, White blood cell count Platelet count, Na, Potassium, Chlorur, Urea, Creatinine, Uric acid, Plasma osmolality, Urine osmolality, Alanine transaminase , Aspartate transaminase , Urine specific gravity, TREATMENT MODALITY Diuretics Intravenous hydration by isotonic saline ECHOCARDIOGRAPHY: Left ventricular end-diastolic diameter, Left ventricular end-systolic diameter, Ejection fraction(%), Left Atrium diameter, Aortic diameter, Right atrium diameter, Interventricular septum, Posterior wall thickness, Mitral insufficiency, Pulmonary insufficiency, Systolic pulmonary artery pressure, Tricuspid insufficiency | 6 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bioimpedance spectroscopy, Hypervolemia, Hypovolemia
A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19

Study Overview
=================
Brief Summary
-----------------
The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19. This study is intended to be registered with the participants who: Have taken PAXLOVID PACK and have no history of using this medicine. Are 12 years and older All participants will receive PAXLOVID, a standard treatment for COVID-19. Participants will take PAXLOVID 2 times a day by mouth or as prescribed. We will examine the experiences of people taking PAXLOVID. This will help us determine if PAXLOVID is safe and effective. Participants will be followed up for 28 days after taking PAXLOVID. During this time, participants will be closely watched for the safety and effects of PAXLOVID.

Detailed Description
-----------------
This is a multicenter cohort study to be conducted in individuals with SARS-CoV-2 infection who are treated with this product, and the investigator will enter the information required in this study in the case report forms (CRFs) based on the information obtained through medical records.

Official Title
-----------------
General Investigation for PAXLOVID PAC

Conditions
-----------------
SARS-CoV-2 Infection

Intervention / Treatment
-----------------
* Drug: nirmatrelvir / ritonavir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who are administered PAXLOVID PACK and have no history of using this drug. Exclusion Criteria: There are no exclusion criteria for this study.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PAXLOVID PACK<br>Subjects administered PAXLOVID PACK | Drug: nirmatrelvir / ritonavir<br>* The usual dosage in adults and pediatric patients (≥12 years of age weighing ≥40 kg) is 300 mg of Nirmatrelvir and 100 mg of ritonavir all taken together orally twice daily for 5 days.<br>* Other names: PAXLOVID PACK;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse drug reactions |  | 34 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ratio of subjects with worsening severity |  | 34 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nirmatrelvir, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), coronavirus disease 2019 (COVID-19), Paxlovid
Biomarker Correlates of Radiologic Imaging

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assemble a collection of urine and blood samples for the development and validation of biomarkers potentially useful in correlating or improving the diagnostic utility of abdominal imaging.

Official Title
-----------------
Biomarker Correlates of Radiologic Imaging

Conditions
-----------------
Abdominal CT Imaging Performed as Standard of Care

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and older Undergoing abdominal CT imaging (standard of care) Signed, informed consent Exclusion Criteria: Patients on dialysis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantitative measures | Confirm the ability of quantitative measure of AQP-1 and ADFP by ELISA from urine and blood samples to develop and validate an assay for patients with renal cancer. | at enrollment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| differentiation of cancerous from non-cancerous renal mass | Correct determination of tumor burden and differentiation of cancerous from non-cancerous renal mass. | at analysis | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CT imaging
Effects of Fetal, Infant, and Early Childhood Exposures on Adult Cancer Risk in Women

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Gathering information about pregnancy, infancy, and early childhood exposures may help doctors identify cancer risk factors, and may help the study of cancer. PURPOSE: This natural history study is looking at the effects of fetal, infant, and early childhood exposures on adult cancer risk in women.

Detailed Description
-----------------
OBJECTIVES: Determine if fetal, infant, and early childhood exposures are associated with adult cancer risk in women. OUTLINE: Mothers of nurses complete questionnaires to collect maternal data, such as pregnancy weight gain, diet during pregnancy, maternal pre-eclampsia, gestational diabetes, gestational age at birth, birth weight, and infant feeding practices. Maternal data is linked to other data collected from critical time periods in the nurses's life cycle, such as menarche, first pregnancy, or adult dietary intake.

Official Title
-----------------
Fetal, Infant and Early Childhood Antecedents of Cancer in Women: Maternal Cohort Study of the Nurses' Health Studies

Conditions
-----------------
Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific

Intervention / Treatment
-----------------
* Other: questionnaire administration
* Procedure: evaluation of cancer risk factors


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Mother of a nurse who is a participant in the Nurses' Health Studies I and II Nurse free of cancer in the year 2000 PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaire administration|nan|
|Procedure: evaluation of cancer risk factors|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnosis of incident cancers and other chronic diseases |  |  | 
| Mortality |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
breast cancer, unspecified adult solid tumor, protocol specific
Expanded Access Protocol Using HBOC-201

Study Overview
=================
Brief Summary
-----------------
The purpose of this protocol is to provide treatment with HBOC-201 to patients with life-threatening anemia for whom allogeneic blood transfusion is not an option. HBOC 201 [hemoglobin glutamer - 250 (bovine)] has been previously studied as an alternative to blood transfusions in severely anemic patients needing a way to enhance tissue oxygenation. HBOC-201 is purified, cross-linked and polymerized acellular bovine hemoglobin in a modified lactated Ringer's solution, and does not require blood compatibility.

Official Title
-----------------
Expanded Access Protocol Using HBOC-201 to Treat Patients With Life Threatening Anemia, for Whom Blood is Not an Option

Conditions
-----------------
Anemia

Intervention / Treatment
-----------------
* Biological: HBOC-201


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients ≥ 18 years of age Critically ill patients with hemoglobin ≤ 6 g/dL (or 7-8 g/dL with significant active bleeding), and physiologic evidence of critical ischemia, for example: elevated troponins, altered mental status, acute renal failure, lactic acidosis or evidence of central nervous system acute deficits Patients or their Legally Authorized Representative who are able and willing to provide informed consent Blood is not an option due to: refusal of transfusion lack of compatible red blood cells Exclusion Criteria: Patients with known hypersensitivity or allergy to beef products Patients with pre-existing uncontrolled hypertension, heart failure, renal failure, circulatory hypervolemia or systemic mastocytosis* Patients who are eligible for blood transfusions Patients who are > 80 years old* on a case by case and quality of life determination

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Comparing New Prothesis PROPRIO-FOOT® Versus Usual Prothesis Tasks Tibial Amputees

Study Overview
=================
Brief Summary
-----------------
Evaluate a new porosthetic device in lower limb amputees.

Detailed Description
-----------------
Randomisation between usual and new prosthesis Cross over study of walking performance and VO2 on treadmill with the two devices after 1 month adaptation to each system.

Official Title
-----------------
Comparaison du Pied Bionique Proprio-Foot® Versus le Pied Habituel Chez Les amputés Tibiaux

Conditions
-----------------
Lower Limb Amputation at Ankle (Injury)

Intervention / Treatment
-----------------
* Device: propriofoot prosthesis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tibial amputation Ability top walk on treadmill Stable prosthesis for at least 3 months Exclusion Criteria: Bilateral amputation Cancer Absence of consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Propriofoot prosthesis<br>New propriofoot prosthesis is worn instead of usual prosthesis foer 1 month | Device: propriofoot prosthesis<br>* Adaptation of the device and evaluation after 1 month at home using the studied device<br>|
| No Intervention: Control<br>Usual prosthesis is worn for 1 month | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| oxygen consumption | Measurement on treadmill | 1 mois after adpatation of the selected device |
Assessing and Reducing Risk of Violent Re-Injury Among Victims of Urban Violence

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to develop a program to help people to lower their chances of being violently injured again.

Official Title
-----------------
Assessing and Reducing Risk of Violent Re-Injury Among Victims of Urban Violence: A Randomized Clinical Trial

Conditions
-----------------
Violence

Intervention / Treatment
-----------------
* Behavioral: Motivational Interviewing
* Other: Treatment as Usual


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 18-65 years intentionally injured in community violence. admitted to a Level 1 trauma center able to provide voluntary informed consent Exclusion Criteria: under the age of 18 or over the age of 55. not fluent in the English language patients with suspected mental retardation or active psychosis as determined by brief clinical screen. patients currently in legal detention status

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Motivational Interviewing<br>Receive brief hospital-based intervention | Behavioral: Motivational Interviewing<br>* Brief hospital-based intervention, rooted in motivational interviewing<br>|
| Other: Treatment as Usual<br>Treatment as Usual | Other: Treatment as Usual<br>* treatment as usual<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Risk Factors for Violence | interview of risk factors | 3 months |
Clinical Trail to Evaluate the Efficacy and Safety of Adhesion Barrier Mediclore Versus no Treatment in Patients With Total Thyroidectomy

Study Overview
=================
Brief Summary
-----------------
A randomized, single-blind, multi-center, Phase III clinical trial to evaluate the efficacy and safety of adhesion barrier Mediclore versus no treatment in patients with total thyroidectomy

Official Title
-----------------
A Randomized, Single-blind, Multi-center, Phase III Clinical Trail to Evaluate the Efficacy and Safety of Adhesion Barrier Mediclore Versus no Treatment in Patients With Total Thyroidectomy

Conditions
-----------------
Patients With Thyroidecomy (Scheduled)

Intervention / Treatment
-----------------
* Device: Mediclore


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent Male or female at least 20 years of age Patients without clinically significant lab Patients scheduled for thyroidectomy Exclusion Criteria: Another clinical trials within 1 month History of previous surgery on same position Anticoagulant, general steroids within a week from surgery Immunosuppression or autoimmune disease General or local infection Serious diseases (heart failure, renal failure, liver failure, uncontrolled hypertentsion, diabetes mellitus, coagulation deficiencies) Incompatible medications History of drug or alcohol abuse, mental disorder Pregnant or lactating women and fertile women who is not using proper contraceptive method History of esophagus diseases Keloid symptoms

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mediclore<br>adhesion barrier Mediclore 5cc, to apply medical device fully around thyroid gland following thyroidectomy | Device: Mediclore<br>* to apply mediclore fully around thyroid gland<br>|
| No Intervention: No treatment<br>No treatment, standard treatment for thyroidectomy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| adhesion incidence rate following 8 weeks |  | 8 weeks |
Cerebral Bloodflow and Carbondioxide Reactivity During Mild Therapeutic Hypothermia in Patients After Cardiac Arrest

Study Overview
=================
Brief Summary
-----------------
Survivors of a cardiac arrest frequently develop severe postanoxic encephalopathy. Derangements in cerebral blood after return of spontaneous circulation play an important role in the pathogenesis of postanoxic encephalopathy. In the present study we examine the effect of mild therapeutic hypothermia on cerebral blood flow and carbondioxide reactivity in patients after cardiac arrest.

Official Title
-----------------
Cerebral Bloodflow and Carbondioxide Reactivity During Mild Therapeutic Hypothermia in Patients After Cardiac Arrest

Conditions
-----------------
Cardiac Arrest, Post-Anoxic Encephalopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult patients GCS after return of circulation < 7 Induced mild hypothermia for 24 hours primary rhythm ventricular fibrillation Exclusion Criteria: Thrombolysis Cardiogenic shock with expected survival < 24 hrs Pregnancy No informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Treatment for Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
The relationship between immune inflammation-related protein complexes inblood and recurrence or metastasis of ovarian cancer will be studied

Detailed Description
-----------------
100 cases in normal ovarian control group, 100 cases in benign ovarian disease group and 100 cases in malignant ovarian epithelial carcinoma group will be studied. Change regularity of ovarian cancer specific immune inflammation-related protein complexes in blood will be studied. The relationship between disease-specific protein complexes and pathological state of patients will be analyzed.

Official Title
-----------------
Evaluation of Prognostic Monitoring for Women Who Have Completed Standard Via Analysis of Immunoinflammation-related Protein Complexes in Blood

Conditions
-----------------
Ovarian Cancer

Intervention / Treatment
-----------------
* Other: Normal clinical treatment without intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female Normal ovary control Ovarian benign disease Ovarian malignant epithelial carcinoma Exclusion Criteria: Male Age above 70 Suffering from other malignant tumors Non-compliant patient

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Normal clinical treatment without intervention|Normal clinical treatment without intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immune Inflammation-Related Protein Pomplexes | The change of immune inflammation-related protein complexes | 2 years |